Loading...

SMMT SUMMIT THERAPEUTICS INC US FDA Inspections 8-K Filing

SMMT

SMMT

SUMMIT THERAPEUTICS INC

(SMMT)

2024 8-K

Clinical Trial Results

Capital Raise Announcement

Expansion Announcement

Clinical Trial Update

Product Expansion

Financial Statements

Clinical Trials

Clinical Trials

Financial Results

Management Changes

Financial Update

Q3 Earnings Report

Stock Sale Agreement

Trial Data Announcement

Financial Results Announcement

Lease Agreement and Directo...

Resignation and Annual Meeting

Private Placement and Licen...

Positive Data from HARMONi-...

Approval of ivonescimab in ...

Distribution Agreement

Financial Results Announcement

Appointment of Director

Management Changes

Data Announcement

Presentation at Healthcare ...

Conference Presentation

Results of Operations and F...

Presentation at Conference

Conference Participation

Financial Condition

Participation Announcement

Results of Operations and F...

Investment and Appointment

Earnings Reports

Annual Meeting of Stockholders

Earnings Report

Other Special Situation

Registration Statement for ...

Results of Operations and F...

Rights Offering Results

Rights Offering

Rights Offering

Rights Offering

Material Definitive Agreement

Financial Results

External Links:

The National Medical Products Administration (NMPA) in China has approved ivonescimab in combination with chemotherapy for use in patients with non-small cell lung cancer who have progressed after treatment with an EGFR tyrosine kinase inhibitor (TKI).

AI Assistant

SUMMIT THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.